TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01025440

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure
Description: Continuous Positive Airway Pressure (CPAP) Dose: A flow (35 L/min) or pressure (btw 4 and 20 cmH20 -individual to each subject) is set on the device.~Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required)~Duration:

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure
Description: Continuous Positive Airway Pressure (CPAP) Dose: A flow (35 L/min) or pressure (btw 4 and 20 cmH20 -individual to each subject) is set on the device.~Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required)~Duration:
Study: NCT03326505

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical cord derived Mesenchymal Stem Cells
Description: Allogenic umbilical cord derived stem cells which are to be injected intrathecally as a treatment option for consenting MS patients
Study: NCT04124835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swiss Ball
Description: Top narrow (DeLee Plan -5 to -1 or Hodge Plan 1-3) Retroversion, lateralization and pelvic circumference exercises with abducted hips and external rotation will be encouraged. Exercises according to fetal positioning: Four ball-assisted supports and / or biped stance with anterior trunk inclination with asymmetrical opening of lower limbs with the aid of the ball. The hips will be in abduction and external rotation.~Lower Narrow (DeLee Plan +1 to +5 or Hodge Plan 3-4) Pelvic anteversion, tilt, and circumference exercises with abducted hips and internal rotation will be encouraged. Exercises according to fetal positioning: Four ball-assisted supports and / or biped stance with anterior trunk inclination with asymmetrical opening of lower limbs with the aid of the ball. The hips will be in abduction and internal rotation.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Grup
Description: Habitual Care of the Service.
Study: NCT01662817

Intervention type: BEHAVIORAL
Intervention: Intervention
Description: PCP receives one day training in depression screening guidelines and uses guidelines for six months
Study: NCT03326505

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical cord derived Mesenchymal Stem Cells
Description: Allogenic umbilical cord derived stem cells which are to be injected intrathecally as a treatment option for consenting MS patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised physical therapy
Description: A combined physical therapy program of Balance, strengthening and endurance exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised physical therapy
Description: A combined physical therapy program of Balance, strengthening and endurance exercises
Study: NCT03451734

Intervention type: DRUG
Intervention: antipsychotic medications
Description: olanzapine, risperidone, aripiprazole, amisulpride, ziprasidone, and haloperidol groups

Intervention type: DRUG
Intervention: antipsychotic medications
Description: olanzapine, risperidone, aripiprazole, amisulpride, ziprasidone, and haloperidol groups

Intervention type: DRUG
Intervention: adjunctive group
Description: antipsychotic plus placebo, antipsychotic plus sulforaphane(3 tables per day, consisting of 30 mg of SFN-glucosinolate per day), and antipsychotic plus minocycline(200mg per day) groups.

Intervention type: DRUG
Intervention: metformin and lifestyle intervention
Description: different dose metformin combines lifestyle intervention

Intervention type: DRUG
Intervention: metformin and lifestyle intervention
Description: different dose metformin combines lifestyle intervention
Study: NCT03450018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLC-0111
Description: Oral SLC-0111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Injection
Description: 1000 mg/m\^2 IV
Study: NCT03158883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab: 10 mg/kg administered by IV infusion q2w (1 cycle = 14 \[±2\] days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab: 10 mg/kg administered by IV infusion q2w (1 cycle = 14 \[±2\] days).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SAR)
Description: SAR: the prescription dose will be 50 Gy over 5 fractions of 10 Gy each on an every 2 day basis (i.e., 2-3 treatments per week, with a minimum of 40 hours and a maximum of 96 hours between treatments) and completed within 1.5-2 weeks. SAR treatment will not be repeated.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SAR)
Description: SAR: the prescription dose will be 50 Gy over 5 fractions of 10 Gy each on an every 2 day basis (i.e., 2-3 treatments per week, with a minimum of 40 hours and a maximum of 96 hours between treatments) and completed within 1.5-2 weeks. SAR treatment will not be repeated.
Study: NCT03314766

Intervention type: DEVICE
Intervention: IC-8 IOL
Description: Patients previously implanted with an IC-8 IOL contralaterally or bilaterally will be evaluated for their long-term visual functions and overall satisfaction at least 12 months post-implantation
Study: NCT00455663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Adaptation Training
Description: Environmental supports for all independent living skills

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharm-Cognitive Adaptation Training
Description: Environmental supports for medication and appointment adherence
Study: NCT01662817

Intervention type: BEHAVIORAL
Intervention: Control
Description: PCP manages depression in the usual way for six months
Study: NCT05411666

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Saline solution maintenance of the CVC
Description: Saline solution maintenance of the Central venous catheter (CVC) - Celsite IMPLANTOFIX from B\|Braun, according to local standard procedures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No maintenance of the CVC
Description: No maintenance of the Central venous catheter (CVC) - Celsite IMPLANTOFIX from B\|Braun. Just visual inspection to local site of CVC insertion.
Study: NCT02459912

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Unilateral Nerve-Sparing Cryoablation of the Prostate
Description: The side of the prostate affected by cancer will be treated with nerve-sparing cryoablation in two freeze-thaw cycles under transrectal ultrasound guidance. The unaffected side of the prostate will not be treated.
Study: NCT00455663

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Medication follow-up and limited case management provided by local community mental health authority
Study: NCT00903383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX3305 low dose
Description: A low dose of LX3305; daily oral intake for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX3305 mid dose
Description: A mid dose of LX3305; daily oral intake for 12 weeks
Study: NCT02459912

Intervention type: DEVICE
Group type: OTHER
Intervention: Precise Cryoablation System with IceRod Needles
Description: Galil Medical Precise Cryoablation System with IceRod Needles will be used for performing Unilateral Nerve-Sparing Cryoablation
Study: NCT04024345

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Barratt Simplified Measure of Social Status (BSMSS)
Description: Questionnaire that evaluates cultural identity, educational level and occupation of the subject and the subject's parents and spouse (if any)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Global Assessment of Functioning scale (GAF)
Description: Used to measure overall levels of functionality of an individual

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: General Self-Efficacy Scale (GSES)
Description: Psychometric scale that is designed to assess optimistic self-beliefs to cope with a variety of difficult demands in life

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Perceived Stress Scale (PSS)
Description: To assess the perceived stress

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Coping Orientation to Problems Experienced (Brief COPE),
Description: It evaluates the subject's coping style through investigation of problem-solving abilities and emotional fluctuation, as a response to stressful situations

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multidimensional Scale of Perceived Social Support (MSPSS)
Description: to explore the subject's social support system
Study: NCT00288366

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ziprasidone vs. aripiprazole
Description: ziprasidone vs. aripiprazole dosed according to package insert

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aripiprazole vs. ziprasidone
Description: aripiprazole vs. ziprasidone dosed according to package insert
Study: NCT00903383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX3305 high dose
Description: A high dose of LX3305; daily oral intake for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo dosing with daily oral intake for 12 weeks
Study: NCT00288366

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aripiprazole vs. ziprasidone
Description: aripiprazole vs. ziprasidone dosed according to package insert
Study: NCT04075071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teacher-Child Interaction Training - Universal
Description: Teacher-Child Interaction Training - Universal (TCIT-U) is an empirically-supported classroom-based intervention designed to strengthen teacher-child relationships, reduce and prevent child behavior problems, and promote social-emotional skills. TCIT-U is based in behavioral and attachment principles and was developed as a modification of Parent-Child Interaction Therapy (PCIT), an evidence-based treatment with well-established support for decreasing disruptive child behaviors and parental stress with children ages two to seven years old. In TCIT-U, teachers of children, preschool through second grade, are taught and coached in skills to manage challenging classroom behaviors and improve the quality of relationships. TCIT-U is delivered to teachers through group didactic training and live individualized coaching.
Study: NCT02477332

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QGE031

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QGE031

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QGE031

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QGE031

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02993146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00109538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonafarnib
Description: 200 mg twice daily (BID, ie, approximately 12 hours apart with food), oral, continuously, or until unacceptable toxicity or transformation to AML, or disease progression, or other discontinuation criteria

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID, oral, continuously, or until unacceptable toxicity or transformation to AML, or disease progression, or other discontinuation criteria
Study: NCT02291731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous use of topical autologous serum
Description: Silicone-hydrogel SCLs combined with 20% (v/v) autologous serum eye drops were used until complete re-epithelialization. SCLs were removed after total re-epithelialization and patients were subsequently randomized divided into two groups: (1) with and (2) without continuous use of topical autologous serum for an additional 2 weeks after SCLs removal.
Study: NCT05304169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprorelin Acetate (Eligard® 45 mg).
Description: Semiannually Leuprorelin Acetate (Eligard® 45 mg).
Study: NCT01440491

Intervention type: OTHER
Group type: OTHER
Intervention: Physiotherapy exercise
Description: once a day, during 15 minutes, for 12 weeks
Study: NCT00910442

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glutathione precursors
Description: HIV+ patients were assigned to 7 day diets containing either NAC or Gln

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutathione precursors
Description: HIV+ patients were assigned to 7 day diets containing either NAC or Gln
Study: NCT02219022

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Study: NCT02993146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropidoxuridine
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole-Brain Radiotherapy
Description: Undergo WBRT
Study: NCT02516514

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-sampling strategy vs multi-sampling strategy for the diagnosis of bacteremia
Description: Comparison between two strategies of blood culture (single-sampling strategy and multi-sampling strategy) for the diagnosis of bacteremia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-sampling strategy vs multi-sampling strategy for the diagnosis of bacteremia
Description: Comparison between two strategies of blood culture (single-sampling strategy and multi-sampling strategy) for the diagnosis of bacteremia
Study: NCT02219022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Study: NCT00892151

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GLUCOFACTS® Deluxe
Description: Diabetes Data Management Software
Study: NCT03748173

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Aerosolized Infasurf
Description: Infants randomized to aerosol treatment will receive Infasurf® aerosol at a rate of 12 ml/hour (the maximal rate using the Solaris CAG). The initial treatment will be for 60 minutes, with reevaluation every 30 minutes thereafter, with a maximum dose of 6 mL/Kg body weight or 2 hours of aerosolization. Treatment will be stopped after 60 minutes (and subsequently at 30-minute intervals) if a 2 point reduction in bronchiolitis score or a score ≤ 4 is achieved. Treatment will also be stopped at any time should there be evidence of other-than-transient deterioration in oxygenation or clinical status or for any serious adverse effect deemed by the infant's clinician to be possibly related to the drug administration.
Study: NCT00743067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1363089 (formerly XL880)
Description: GSK1363089 will be available as solid capsules with dose unit of 20, 100 and 200 mg. Subjects will administer GSK1363089 capsules orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1363089 (formerly XL880)
Description: GSK1363089 will be available as solid capsules with dose unit of 20, 100 and 200 mg. Subjects will administer GSK1363089 capsules orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1363089 (formerly XL880)
Description: GSK1363089 will be available as solid capsules with dose unit of 20, 100 and 200 mg. Subjects will administer GSK1363089 capsules orally
Study: NCT02915900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gonadotropin removal test
Description: Patient receives hormone dosage adjusted according to the results of the Gonadotropin removal test.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine IVF method
Description: Patient receives hormone dosage according to the standard dosage regimen, without revealing the results of the Gonadotropin removal test to the clinician.
Study: NCT06577038

Intervention type: DEVICE
Intervention: PCI with use of IVL
Description: Use of IVL for the treatment of calcific coronary artery lesions at operator's discretion
Study: NCT00527293

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: If chemotherapy is planned, it must begin no earlier than two weeks following completion of radiation. If chemotherapy is given first, a minimum of 2 weeks from the last cycle must elapse prior to the start of radiation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: If chemotherapy is planned, it must begin no earlier than two weeks following completion of radiation. If chemotherapy is given first, a minimum of 2 weeks from the last cycle must elapse prior to the start of radiation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: 3-dimensional conformal radiotherapy twice daily for 5-10 days.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: Patients undergo partial breast irradiation comprising either MammoSite® brachytherapy twice daily for 5-10 days
Study: NCT01558440

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Infant Formula
Description: A diet that is being fed to the young infants.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: F-100
Description: • F-100: The estimated PRSL for F-100 is 360 mOsm/L or 53 mOsm/100kcal and in a young infant growing normally this could exceed the excretory capacity of the kidney with the risk of hypernatremic dehydration. In the rehabilitation phase, however, severely malnourished children grow extremely rapidly and the potential solutes (e.g. protein, potassium) are deposited in lean tissue and do not present to the kidney for excretion. Thus, although the potential RSL is high, this has been assumed to be a theoretical risk for rapidly growing infants

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diluted F-100
Description: 300 ml of water is added to 1000 ml of f-100
Study: NCT00316082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Coated tablets, Oral, 2.5 mg, QAM, Daily (6 months ST, 12 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Coated tablets, Oral, 2.5 mg titrated to 5mg, QAM, Daily (6 months ST, 12 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Coated tablets, Oral, 5mg, QAM, Daily, (6 months ST, 12 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Coated tablets, Oral, 5mg QPM, Daily (6 months ST, 12 months LT)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Coated tablets, Oral, 0mg, Daily (6 months ST, 12 months LT)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: Tablets, Oral, 500-2000 mg, as needed (12 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets, Oral, 500-2000 mg, as needed (12 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets, Oral, 500-2000 mg, as needed (12 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets, Oral, 500-2000 mg, as needed (12 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets, Oral, 500-2000 mg, as needed (12 months LT)
Study: NCT04169308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Restylane-L® Filler injection
Description: Restylane-L® Filler injection into the soft tissue of the nose
Study: NCT05361226

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Accuracy measurement
Description: Three months following the implant placement, patients were called back to the implant clinic to record the actual implant position with the digital impression technique. Full mouth scans were done by using the intraoral scanner (Trios 3, 3Shape, Copenhagen, Denmark). The surface scans were then exported as an STL file and were imported to coDiagnostiX software. The Treatment evaluation tool function tool was used to measure the accuracy of the implant placement which measured the amount of deviation of the placed implant from the planned position. The outcomes were generated into three main parameters.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accuracy measurement
Description: Three months following the implant placement, patients were called back to the implant clinic to record the actual implant position with the digital impression technique. Full mouth scans were done by using the intraoral scanner (Trios 3, 3Shape, Copenhagen, Denmark). The surface scans were then exported as an STL file and were imported to coDiagnostiX software. The Treatment evaluation tool function tool was used to measure the accuracy of the implant placement which measured the amount of deviation of the placed implant from the planned position. The outcomes were generated into three main parameters.
Study: NCT04605796

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Toripalimab combined with Bevacizumab
Description: Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w). combined with Lenvatinib 15 mg/kg (IV infusion, every 3 weeks (q3w).. Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol.
Study: NCT03549650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentosan Polysulfate Na 100Mg Cap
Description: Participants will be randomly assigned to receive Pentosan Polysulfate Na 100Mg Cap TID for 6 weeks.~For blinded distribution, each bottle of medications will be labeled with a random number for identification.~The study participants will be monitored every 2 weeks with phone calls from the study team to evaluate their condition and decide if the medication is tolerated and whether it should be continued or stopped.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Participants will be randomly assigned to receive Placebo oral capsule TID for 6 weeks.~For blinded distribution, each bottle of medications will be labeled with a random number for identification.~The study participants will be monitored every 2 weeks with phone calls from the study team to evaluate their condition and decide if the medication is tolerated and whether it should be continued or stopped.
Study: NCT01655290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gadovist® (Gadobutrol), Multihance® (Gadobenate dimeglumin)
Description: Other (Diagnostic)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gadovist® (Gadobutrol), Multihance® (Gadobenate dimeglumin)
Description: Other (Diagnostic)